UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.6005-6015

2013

Volltextzugriff (PDF)

AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

Clinical cancer research, 2020-02, Vol.26 (4), p.922-934

2020

Volltextzugriff (PDF)

Laser capture microdissection and genetic analysis of carbon-labeled Kupffer cells

World journal of gastroenterology : WJG, 2009-04, Vol.15 (14), p.1708-1718

2009

Volltextzugriff (PDF)

A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity

British journal of pharmacology, 2021-02, Vol.178 (3), p.600-613

2021

Volltextzugriff (PDF)

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model

Journal of antimicrobial chemotherapy, 2017-10, Vol.72 (10), p.2796-2803

2017

Volltextzugriff (PDF)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Oncoimmunology, 2022-12, Vol.11 (1), p.2083755-2083755

2022

Volltextzugriff (PDF)

Generation and characterization of an immunogenic dendritic cell population

Journal of immunological methods, 2008-03, Vol.332 (1), p.18-30

2008

Volltextzugriff (PDF)

Kupffer Cells Abrogate Cholestatic Liver Injury in Mice

Gastroenterology (New York, N.Y. 1943), 2006-03, Vol.130 (3), p.810-822

2006

Volltextzugriff (PDF)

Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2500-2500

2019

Volltextzugriff (PDF)

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Journal of medicinal chemistry, 2020-12, Vol.63 (24), p.15564-15590

2020

Volltextzugriff (PDF)

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Blood, 2021-05, Vol.137 (21), p.2947-2957

2021

Volltextzugriff (PDF)

Abstract 1664: Inhibition of arginase in combination with radiation therapy shows increased immune-activation and anti-tumor activity in syngeneic tumor models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1664-1664

2021

Volltextzugriff (PDF)

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1813-1813

2021

Volltextzugriff (PDF)

Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.306-306

2018

Volltextzugriff (PDF)

Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.967-967

2020

Volltextzugriff (PDF)

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

Blood, 2021-11, Vol.138 (Supplement 1), p.2274-2274

2021

Volltextzugriff (PDF)

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Blood, 2018-11, Vol.132 (Supplement 1), p.3946-3946

2018

Volltextzugriff (PDF)

Abstract 297: AZD4573: Mechanistic PKPD model linking CDK9 inhibition to Mcl1 depletion and induction of apoptosis in preclinical AML model

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.297-297

2018

Volltextzugriff (PDF)

Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.310-310

2018

Volltextzugriff (PDF)

Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

Molecular cancer therapeutics, 2023-05, Vol.22 (5), p.630-645

2023

Volltextzugriff (PDF)

Abstract 4295: AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4295-4295

2017

Volltextzugriff (PDF)

Abstract 4263: A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4263-4263

2018

Volltextzugriff (PDF)

Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1650-1650

2018

Volltextzugriff (PDF)

Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models

Blood, 2017-12, Vol.130, p.4113-4113

2017

Volltextzugriff (PDF)

Abstract B112: Synergistic anti-lymphoma activity of ibrutinib and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma is maintained in vivo on an intermittent schedule

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B112-B112

2015

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy

AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

Laser capture microdissection and genetic analysis of carbon-labeled Kupffer cells

A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Generation and characterization of an immunogenic dendritic cell population

Kupffer Cells Abrogate Cholestatic Liver Injury in Mice

Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Abstract 1664: Inhibition of arginase in combination with radiation therapy shows increased immune-activation and anti-tumor activity in syngeneic tumor models

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL

Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Abstract 297: AZD4573: Mechanistic PKPD model linking CDK9 inhibition to Mcl1 depletion and induction of apoptosis in preclinical AML model

Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1

Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

Abstract 4295: AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma

Abstract 4263: A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model

Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies

Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models

Abstract B112: Synergistic anti-lymphoma activity of ibrutinib and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma is maintained in vivo on an intermittent schedule

Suchergebnisse filtern